Susquehanna International Group, LLP Reata Pharmaceuticals Inc Transaction History

Susquehanna International Group, LLP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$79.22 - $105.37 $1.41 Million - $1.88 Million	-17,811 Reduced 17.48%	84,059 $8.57 Million
Q1 2023 May 16, 2023	BUY	$30.85 - $93.17 $2.68 Million - $8.09 Million	86,819 Added 576.83%	101,870 $9.26 Million
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $146,810 - $279,105	6,628 Added 78.69%	15,051 $571,000
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $163,490 - $307,355	8,423 New	8,423 $212,000
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $73,100 - $104,547	731 Added 16.75%	5,096 $513,000
Q2 2021 Aug 11, 2021	SELL	$78.27 - $151.29 $5.9 Million - $11.4 Million	-75,333 Reduced 94.52%	4,365 $618,000
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $4.53 Million - $6.39 Million	48,107 Added 152.28%	79,698 $7.95 Million
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $6.14 Million - $11.1 Million	-60,130 Reduced 65.56%	31,591 $3.91 Million
Q3 2020 Nov 16, 2020	BUY	$93.53 - $163.34 $3.16 Million - $5.53 Million	33,833 Added 58.45%	91,721 $8.94 Million
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $3.99 Million - $5.57 Million	31,562 Added 119.89%	57,888 $9.03 Million
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $4.64 Million - $9.25 Million	-37,352 Reduced 58.66%	26,326 $3.8 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $2.36 Million - $6.9 Million	31,665 Added 98.91%	63,678 $13 Million
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $1.7 Million - $2.28 Million	23,795 Added 289.55%	32,013 $2.57 Million
Q2 2019 Aug 16, 2019	BUY	$77.72 - $94.35 $638,702 - $775,368	8,218 New	8,218 $775,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.